

ORAL ORDER: Having considered the parties' Joint Status Report (No. 21-691, D.I. 733), IT IS HEREBY ORDERED that, on or before June 17, 2025, Plaintiffs Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited (collectively, the "Jazz Parties") shall file with the Court their opening brief and any supporting papers "address[ing] whether Avadel should and/or can be enjoined from seeking FDA approval for an idiopathic hypersomnia (IH') indication for LUMRYZ[] prior to the expiration of the '782 patent in light of the Federal Circuit's decision," id. at 1, in Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC, No. 2024-2274, ___ F.4th ___, 2025 WL 1298920 (Fed. Cir. May 6, 2025). IT IS FURTHER ORDERED that, on or before July 29, 2025, Defendant Avadel CNS Pharmaceuticals shall file with the Court its answering brief and any supporting papers. IT IS FURTHER ORDERED that, on or before August 19, 2025, the Jazz Parties may file with the Court a reply brief. IT IS FURTHER ORDERED that, in accordance with Local Rule 7.1.3, the parties opening and answering briefs shall be no longer than twenty (20) pages and the reply brief shall be no longer than ten (10) pages, in each instance exclusive of any table of contents or table of citations. The Court will schedule an oral argument and/or an evidentiary hearing, if necessary, after considering the parties' briefing. ORDERED by Judge Gregory B. Williams on 5/29/2025. Associated Cases: 1:21-cv-00691-GBW, 1:21-cv-01594-GBW(lnb) (Entered: 05/29/2025)